Turn Therapeutics Inc. TTRX
9.35 USD -0.79 (-7.75%)
Regular-session close
9.35 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
9.28 Day range 10.28
2.71 52-week range 15.34
- YTD
- +137.18%
- 1 year
- +128.48%
Benzinga news
benzinga.com Turn Therapeutics Q3 EPS $(0.21) Misses $(0.09) Estimate Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.09) by 162.5 percent. This is a 200 percent decrease over losses of…
benzinga.com This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded SAFE, CNOB, LMT and more.
benzinga.com This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…benzinga.com WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10 WBB Securities analyst Karen Sterling upgrades Turn Therapeutics (NASDAQ:TTRX) from Sell to Hold and maintains the price target from $10 to $10.
benzinga.com This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24 LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
benzinga.com WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…benzinga.com Turn Therapeutics Publishes Peer-Reviewed Research Of GX-03 In Life. In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory…
benzinga.com Why Is Turn Therapeutics Stock Trading Higher Today? Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.benzinga.com Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic Dermatitis Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of…
benzinga.com Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic Dermatitis Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session benzinga.com Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis 92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks…
benzinga.com Turn Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 200 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com US Stocks Mixed; Nasdaq Falls Over 50 Points
benzinga.com Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
